

RD General Agenda Topics – August 10, 2021

Briefings for Michal

- PRIA/registration overview 2/23rd (complete)
- Dicamba 2/18th (complete)
- Sulfoxaflor 3/4th (complete)
- Pet incidents 3/31st (complete)
- FDA/EPA jurisdiction 4/12th (complete)
- SW2 revocation options 5/3rd (complete)
- Antibiotics 5/17th (complete)

Waiting for OPP-IO

- Imidacloprid S18 Hemlock MI
- Kaput Feral Hog Bait petition response

New Active Ingredients (include original PRIA date)

- Tetraniliprole – completed!
- Broflanilide – completed!
- Picarbutrazox – completed!
- Fluxametamide – completed!
- Fluindapyr – completed!
- Trifludimoxazin – completed!
- Ipflufenquin – PD published 6/25. PRIA date **10/29/21** (Original PRIA date 4/19/21) (FB).
- Rekleml – PD published 7/23. PRIA date **8/24/21** (Original PRIA date 4/19/21) (IVB3).
- Isoprothiolane – Import tolerance. PRIA date 10/12/21 (Original PRIA date 10/12/21) (FB)
- Pyflubumide – Import tolerance pilot. PRIA date 12/20/21 (Original PRIA date 12/20/21) (IVB1).
- Florylpicoxamid – working with company on ESA mitigation/ partial effects finding. PRIA date **10/27/21** (Original PRIA date 10/27/21)
- Pyraclonil – working with company on ESA mitigation/CA only rice. PRIA date **11/22/21**. (Original PRIA date 11/22/21)
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021 (FHB). ESA issue. Moving forward with incorporating ESA analysis. Will require lengthy renegotiation per briefing with Ed; companies have been notified.

Other Chemical Actions

- Dicamba
 - Bayer and BASF requesting feedback on pending pre-mixes; sent 75 day letters
 - **USDA conducting EIS** (instead of EA) on dicamba resistant corn; issued a 60-day public comment period 5/8th; Comment period extended to 6/28. Coordinating with AO's OP and regions;
 - **24 (c)s** –
 - NC – denial 3/15th
 - TN – denial 4/9th

- GA – denial 4/23rd
- TX – Notice of intent to deny signed 6/15th; TX withdrew
- GA – Tavium request; heads up from Syngenta; no request
- KS – request withdrawn
- MS – no formal request following pre-consultation discussions
- **AAPCO letter to Administrator** – rec'd 7/14
- **2021 incidents:**
 - Working with WSSA liaison to hear from academics 8/30/21
 - Reaching out to AAPCO on whether a call would be beneficial TBD
- **Antibiotics** – will need to brief the new team (FB)
 - Briefed Michal 5/17th; Received policy feedback on the antibiotic issue; Oxytet – cherry PPIA date of June – delay the action while we work on policy approach

Ex. 5 Deliberative Process (DP)

- **Cyclaniliprole/flonicamid** – first residential use; public process; published proposal!
- **Seresto** – pet collar with high rate of incidents (death and neuro); press inquiries; 6a2 letter sent; updated desk statement to include factual information on FDA vs. EPA; received

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – Michal follow up complete; team identified appropriate “model” MOUs and sent talking points; Ed is reaching out
- COVID-19 Activities – Sect 18s –
 - SW2 – revocation of existing AR, TX S18s based on science and violations – completed!
 - Grignard – (NV, PA, TX, MD; amendment to TN and GA) – completed!
 - Kraton – completed!
 - Ionopure Air – risk issues
 - Acteev Facemasks
- **OIG Audits**

Ex. 5 Deliberative Process (DP)

- **PFAS** – gave update to PMRA during bimonthly registration topics mtg on 7/13

- **Inerts** supply issue – phase 1 completed!; phase 2 – completed!
- **Inert** – Fragrance petition (Pat Quinn) – 2 petition responses scheduled for OGC review in June (Kerry); other petition responses will follow within existing resource constraints
- **CRP** (Child resistant Packaging) testing – industry has requested flexibilities in testing requirements due to COVID impacts; CPSC (whose regulations we use) have issued similar flexibilities. Team recommends issuing some but not all flexibilities. Next steps- COVID workgroup

International

- Bi-monthly meeting with PMRA 7/13th – Seresto – complete
- PMRA – industry JR meeting 6/29th - complete
- WPP meeting – 7/2nd - complete

Business/process/technology

- ISB – FEP/21-day backlog:
 - backlog addressed by end of April; RD SWAT team addressing newer receipts
 - RD SWAT actions - completed!
- eCSF/OPPEL – eCSF May 9th soft launch; OPPEL -TBD
- RD workload analysis – any additional feedback; see meeting summary and action items.
- SF/OPPIN issue in reassigning cases from RD to AD

Speaking Engagements –

People/Personnel/Resources

Ex. 5 Deliberative Process (DP)

CA topics (Karen Morrison):

- Missing environmental hazard statements – RD BC's are generating a response